ArticleJournal for immunotherapy of cancer2022

Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.

Roger Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.